Replimune CEO and leadership

Robert Coffin is Founder, President and Chief Research & Development Officer of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.

Experienced Board Director, Chief Financial Officer, and operational leader with over 25 years of international and U.S. life sciences experience. Experience is in various business models and circumstances, from pre-clinical to commercial in biotech, diagnostics, and devices.Board Memberships:Visioneering Technologies Inc., Atlanta (ASX: VTI.AX), Audit Committee Chair, 2017- PresentBiophytis, Paris, France - (Euronext: ALBPS.PA), Audit Committee, 2017 - PresentInternational Institute of New England, a NGO, Boston, MA, Finance Committee Chair, 2016-2019Experience:*Financing: IPO, Venture Capital, Venture and Structured Debt* Strategic Planning and Financial Analysis* Contract Negotiations and Strategic Alliances* Profit Optimization* Process Design and Productivity Improvement

Pamela Esposito is a Chief Business Officer at Replimune Group Inc., Board Member at Accent Therapeutics Inc, and Board Member at KYMERA THERAPEUTICS INC.. She has worked as Chief Business Officer at RA PHARMACEUTICALS INC., Senior VP:Strategic Planning at Angiochem, and VP:Business Development at BioVex. Pamela attended Tufts University School of Medicine and DARTMOUTH COLLEGE.

Experienced business leader with a demonstrated history of working in the biotechnology industry. Skilled in multiple aspects of international oncology marketing, sales, and clinical drug development. Diverse cross functional team leadership experience. Doctor of Philosophy (PhD) focused in Molecular Biology from the University of London.

Robert Coffin is Founder, President and Chief Research & Development Officer of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.

Robert Coffin is Founder, President and Chief Research & Development Officer of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. Rob was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC; Imlygic) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013. T-VEC was approved by the FDA for use in advanced melanoma in October 2015, the first oncolytic therapy or gene therapy to be approved in the US. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.